Cardioselective β-Blockers in Patients with Reactive Airway Disease¶
Salpeter, Ormiston, & Salpeter. (2002). Cardioselective β-Blockers in Patients with Reactive Airway Disease. Annals of Internal Medicine.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Contraindication
- When a clinician orders a non-selective beta-blocker (propranolol) for a patient whose electronic record carries an active asthma diagnosis, the system runs the order against the coded drug–disease exception table and surfaces a point-of-care alert: beta-blockade risks bronchospasm by antagonizing β2 receptors in airway smooth muscle
This sourceQuantifies the airway risk of beta-blockade by receptor selectivity — cardioselective agents did not significantly worsen pulmonary function in mild-to-moderate reactive airway disease across 29 trials — which is what makes the cardioselective switch the right fallback; the receptor mechanism and the order-entry alerting are sourced elsewhere.
- When a clinician orders a non-selective beta-blocker (propranolol) for a patient whose electronic record carries an active asthma diagnosis, the system runs the order against the coded drug–disease exception table and surfaces a point-of-care alert: beta-blockade risks bronchospasm by antagonizing β2 receptors in airway smooth muscle
Verification¶
This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.
Registry ID ref:472b2d7536e3 · see in the full table